Group
anti-claudin 18.2 mAb
Group Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | Other mAbs |
| Mechanism of Action | Anti-Claudin 18.2 antibody |
| Drugs in group | Zolbetuximab |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
No DNA-level radiosensitization (ADCC/CDC-mediated) (Saviano et al., Nature Reviews Cancer, 2026; Xie et al., Journal of Hematology & Oncology, 2026). Theoretically, there is no mechanistic basis for increased in-field adverse events; the dominant class adverse effect is GI (nausea/vomiting) from the antibody, independent of RT.
The data above refer to patients treated with anti-claudin 18.2 mAb as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.